Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
NCT05120284Phase 2Active, not recruiting
- Sponsor
- University of Florida
- Start
- Jul 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dichloroacetate in glioblastoma multiforme (GBM) (2 arms), sponsored by University of Florida. Primary endpoint: Level of phosphorylated PDC protein expressed in surgical tissue. Started Jul 2022; status: active, not recruiting.
02
Drugs
dichloroacetate
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05120284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120284.